<?xml version="1.0" encoding="utf-8"?>
<publicwhip>

<spmotion spid="S2M-3281" date="2005-09-15" filename="day-bb-05_bb-09-15f.htm" url="http://www.scottish.parliament.uk/business/businessBulletin/bb-05/bb-09-15f.htm">
 *S2M-3281 Dr Jean Turner: Scottish Medicines Consortium - Breast Cancer Drug, Arimidex, Approved Ahead of the Rest of the United Kingdom—That the Parliament congratulates the Scottish Medicines Consortium (SMC) for backing, ahead of the rest of the United Kingdom, the use in Scotland of the breast cancer drug, anastrazole (Arimidex) for first-line therapy in the adjuvant treatment of postmenopausal women with oestrogen receptor-positive early invasive breast cancer; notes that in trials this drug cut the risk of cancer returning in older woman to less than one in four, and further notes that the backing is ahead of the appraisal by the National Institute for Health and Clinical Excellence (NICE) who may not be appraising this drug until November 2006 due to funding cuts of £3.5 million. Supported by: Alex Neil*, Mrs Margaret Ewing*, Ms Rosemary Byrne*, Ms Sandra White*, Mike Pringle*, Shiona Baird* 
</spmotion>

<spmotion spid="S2M-3281" date="2005-09-16" filename="day-bb-05_bb-09-16f.htm" url="http://www.scottish.parliament.uk/business/businessBulletin/bb-05/bb-09-16f.htm">
 S2M-3281 Scottish Medicines Consortium - Breast Cancer Drug, Arimidex, Approved Ahead of the Rest of the United Kingdom (lodged on 14 September 2005) Phil Gallie*, Eleanor Scott*, Mr Adam Ingram* 
</spmotion>

<spmotion spid="S2M-3281" date="2005-09-19" filename="day-bb-05_bb-09-19f.htm" url="http://www.scottish.parliament.uk/business/businessBulletin/bb-05/bb-09-19f.htm">
 S2M-3281 Dr Jean Turner:Scottish Medicines Consortium - Breast Cancer Drug, Arimidex, Approved Ahead of the Rest of the United Kingdom—That the Parliament congratulates the Scottish Medicines Consortium (SMC) for backing, ahead of the rest of the United Kingdom, the use in Scotland of the breast cancer drug, anastrazole (Arimidex) for first-line therapy in the adjuvant treatment of postmenopausal women with oestrogen receptor-positive early invasive breast cancer; notes that in trials this drug cut the risk of cancer returning in older woman to less than one in four, and further notes that the backing is ahead of the appraisal by the National Institute for Health and Clinical Excellence (NICE) who may not be appraising this drug until November 2006 due to funding cuts of £3.5 million. Supported by: Alex Neil, Mrs Margaret Ewing, Ms Rosemary Byrne, Ms Sandra White, Mike Pringle, Shiona Baird, Phil Gallie, Eleanor Scott, Mr Adam Ingram, Tommy Sheridan* 
</spmotion>

<spmotion spid="S2M-3281" date="2005-09-20" filename="day-bb-05_bb-09-20f.htm" url="http://www.scottish.parliament.uk/business/businessBulletin/bb-05/bb-09-20f.htm">
 S2M-3281 Scottish Medicines Consortium - Breast Cancer Drug, Arimidex, Approved Ahead of the Rest of the United Kingdom (lodged on 14 September 2005) Mr Jamie Stone* 
</spmotion>

<spmotion spid="S2M-3281" date="2005-09-27" filename="day-bb-05_bb-09-27f.htm" url="http://www.scottish.parliament.uk/business/businessBulletin/bb-05/bb-09-27f.htm">
S2M-3281 Scottish Medicines Consortium - Breast Cancer Drug, Arimidex, Approved Ahead of the Rest of the United Kingdom (lodged on 14 September 2005) Robin Harper* 
</spmotion>

<spmotion spid="S2M-3281" date="2005-09-28" filename="day-bb-05_bb-09-28f.htm" url="http://www.scottish.parliament.uk/business/businessBulletin/bb-05/bb-09-28f.htm">
S2M-3281 Scottish Medicines Consortium - Breast Cancer Drug, Arimidex, Approved Ahead of the Rest of the United Kingdom (lodged on 14 September 2005) John Scott* 
</spmotion>

</publicwhip>
